OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Australian government has issued a Notice of Acceptance for a patent for a key peptide fragment of Thymosin
beta 4 (TB4).
The thymus produces several putative thymic hormones: thymosin
alpha 1, thymulin, and thymopoietin, which have been reported to circulate and to act on both prothymocytes and mature T cells in the periphery, thus maintaining their commitment to the T cell system.
today announced that it has received a patent in Mexico for the treatment of dry eye syndrome and glaucoma, among other medical indications, using Thymosin
beta 4 (T?
A protein called thymosin
beta-4 can provide just the sort of stimulus needed to turn dormant stem cells into Mr.
They also found that thymosin
beta-4, a peptide naturally produced by the body, could reawaken and mobilise these stem cells to repair heart damage.
Researchers at University College London's Institute of Child Health have found that a protein called thymosin
beta 4 can persuade cells found on the outside of the heart to move deeper into the organ where they form cells capable of making blood vessels.
Scientists hope the molecule, called thymosin
beta 4, will open the door to new treatments for heart attack patients.
The new mouse-study findings show that the protein, thymosin
beta-4, prevents cell death after an experimentally induced heart attack and limits the degree of scar tissue formation.
Srivastava said, is to determine the most effective dose, the optimal time to administer thymosin
beta-4 and how long after an attack the protein can be given to be effective.
In tests on mice, the US researchers found their hearts repaired much better after an attack when they were given the protein molecule thymosin
SciClone Pharmaceuticals (San Mateo, CA; 650-358-3456), announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a United States patent covering the use of its lead drug, thymosin
alpha 1, to treat hepatitis C.
Prothymosin [alpha] (ProT [alpha]) is a small, highly acidic protein first isolated as the precursor of thymosin